celecoxib has been researched along with Adenoma, Prostatic in 4 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Celecoxib is effective in the treatment of patients with BPH complaining of refractory nocturia." | 9.13 | Celecoxib for treatment of nocturia caused by benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled study. ( Asgari, SA; Falahatkar, S; Kamran, AN; Mokhtari, G; Pourreza, F, 2008) |
| "Celecoxib is effective in the treatment of patients with BPH complaining of refractory nocturia." | 5.13 | Celecoxib for treatment of nocturia caused by benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled study. ( Asgari, SA; Falahatkar, S; Kamran, AN; Mokhtari, G; Pourreza, F, 2008) |
| "Prostatic inflammation is the driving force in benign prostatic hyperplasia (BPH)." | 1.91 | Cyclooxygenase-2 activates EGFR-ERK1/2 pathway via PGE2-mediated ADAM-17 signaling in testosterone-induced benign prostatic hyperplasia. ( Abdel-Fattah, MM; Abo-El Fetoh, ME; Afify, H; Mohamed, WR; Ramadan, LAA, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abo-El Fetoh, ME | 1 |
| Abdel-Fattah, MM | 1 |
| Mohamed, WR | 1 |
| Ramadan, LAA | 1 |
| Afify, H | 1 |
| Jhang, JF | 1 |
| Jiang, YH | 1 |
| Kuo, HC | 1 |
| Funahashi, Y | 1 |
| O'Malley, KJ | 1 |
| Kawamorita, N | 1 |
| Tyagi, P | 1 |
| DeFranco, DB | 1 |
| Takahashi, R | 1 |
| Gotoh, M | 1 |
| Wang, Z | 1 |
| Yoshimura, N | 1 |
| Falahatkar, S | 1 |
| Mokhtari, G | 1 |
| Pourreza, F | 1 |
| Asgari, SA | 1 |
| Kamran, AN | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| COX-2 Inhibitor Reduces Serum PSA Levels Might Predict a Lower Risk of Prostatic Cancer in Men With LUTS/BPH With an Elevated PSA Level[NCT01678313] | Phase 2 | 140 participants (Actual) | Interventional | 2012-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Efficacy:~Change from Baseline in the International Prostate Symptom Score (IPSS) from baseline and 3 months The International Prostate Symptom Score (IPSS) is an 7 symptom questions including 4 voiding questions (IPSS Voiding), 3 storage questions (IPSS Storage) The symptom score have 6-point scale ranging from 0 Not at all to 5 Almost always.~Total IPSS score = IPSS voiding + IPSS Storage Rang = 0 to 35 (asymptomatic to very symptomatic). Mild = 0 to 7; Moderate = 8 to 19; Severe = 20 to 35~Change = Month 3 minus Baseline value" (NCT01678313)
Timeframe: Baseline and 3 months after initial treatment
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | 3 months | Change | |
| Control Group | 12.0 | 7.70 | -4.31 |
| Study Group | 13.1 | 6.45 | -6.63 |
"Efficacy:~Change from Baseline in the IPSS Storage from baseline and 3 months The IPSS subscore (IPSS Storage) is a 3 symptom questions. The symptom score have 6-point scale ranging from 0 Not at all to 5 Almost always. Each question is assigned points from 0 to 5 indicating increasing severity of the particular symptom.~The total IPSS Storage score can therefore range from 0 to 15 (asymptomatic to very symptomatic).~Change = Month 3 minus Baseline value" (NCT01678313)
Timeframe: Baseline and 3 months after initial treatment
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | 3 months | Change | |
| Control Group | 6.06 | 4.01 | -2.05 |
| Study Group | 5.59 | 3.09 | -2.5 |
"Efficacy:~Change from Baseline in the IPSS Voiding from baseline and 3 months. The IPSS subscore (IPSS Voiding) questionnaires is a 4 symptom questions. The symptom score have 6-point scale ranging from 0 Not at all to 5 Almost always. Each question is assigned points from 0 to 5 indicating increasing severity of the particular symptom.~The total IPSS Voiding score can therefore range from 0 to 20 (asymptomatic to very symptomatic).~Change = Month 3 minus Baseline value" (NCT01678313)
Timeframe: Baseline and 3 months after initial treatment
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | 3 months | Change | |
| Control Group | 5.54 | 3.45 | -2.09 |
| Study Group | 7.55 | 3.84 | -3.71 |
"Efficacy:~Change from Baseline in the maximum flow rate (Qmax) from baseline and 3 months Change = Month 3 minus Baseline value" (NCT01678313)
Timeframe: Baseline and 3 months after initial treatment
| Intervention | mL/s (Mean) | ||
|---|---|---|---|
| Baseline | 3 months | Change | |
| Control Group | 10.0 | 11.9 | 1.9 |
| Study Group | 12.2 | 12.2 | -0.09 |
"Efficacy:~Change from Baseline in the serum PSA level from baseline and 3 months Change = Month 3 minus Baseline value" (NCT01678313)
Timeframe: Baseline and 3 months after initial treatment
| Intervention | ng/mL (Mean) | ||
|---|---|---|---|
| Baseline | 3 months | Change | |
| Control Group | 15.2 | 13.5 | -1.70 |
| Study Group | 10.8 | 9.42 | -1.43 |
"Efficacy:~Change from Baseline in the Void Volume (VV) from baseline and 3 months Change = Month 3 minus Baseline value" (NCT01678313)
Timeframe: Baseline and 3 months after initial treatment
| Intervention | mL (Mean) | ||
|---|---|---|---|
| Baseline | 3 months | Change | |
| Control Group | 175 | 231 | 55.7 |
| Study Group | 259 | 227 | -32.3 |
2 trials available for celecoxib and Adenoma, Prostatic
| Article | Year |
|---|---|
Adding Cyclooxygenase-2 inhibitor to alpha blocker for patients with benign prostate hyperplasia and elevated serum prostate specific antigen could not improve prostate biopsy detection rate but improve lower urinary tract symptoms.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Aged; Biopsy; Celecoxib; Cyclooxygenase 2 Inhibitors | 2013 |
Celecoxib for treatment of nocturia caused by benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled study.
Topics: Aged; Aged, 80 and over; Celecoxib; Cyclooxygenase Inhibitors; Double-Blind Method; Humans; Male; Mi | 2008 |
2 other studies available for celecoxib and Adenoma, Prostatic
| Article | Year |
|---|---|
Cyclooxygenase-2 activates EGFR-ERK1/2 pathway via PGE2-mediated ADAM-17 signaling in testosterone-induced benign prostatic hyperplasia.
Topics: ADAM17 Protein; Animals; Celecoxib; Cyclooxygenase 2; Dinoprostone; ErbB Receptors; Hyperplasia; Inf | 2023 |
Upregulation of androgen-responsive genes and transforming growth factor-β1 cascade genes in a rat model of non-bacterial prostatic inflammation.
Topics: Androgens; Animals; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cytokines; Disease Mod | 2014 |